| Title: |
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod. |
| Authors: |
Jeantin, Lina, Shor, Natalia, Pallix-Guyot, Maud, Roos-Weil, Damien, Bellanger, Agnès, Le Garff-Tavernier, Magali, Papeix, Caroline, Weiss, Nicolas, Pourcher, Valérie |
| Source: |
Journal of Neurology; Feb2024, Vol. 271 Issue 2, p729-732, 4p |
| Subject Terms: |
PROGRESSIVE multifocal leukoencephalopathy, JOHN Cunningham virus, MULTIPLE sclerosis, PEMBROLIZUMAB, FINGOLIMOD, T-cell exhaustion |
| Abstract: |
This letter, published in the Journal of Neurology, discusses the case of a patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) while being treated with fingolimod. PML is a central nervous system infection caused by the reactivation of the John Cunningham virus (JCV), and it is a concern for MS patients treated with certain medications. The patient's PML progressed despite treatment discontinuation and therapeutic plasma exchanges, but they were successfully treated with three cycles of pembrolizumab, an immune checkpoint inhibitor. The use of pembrolizumab for PML in MS patients is still being studied, but it may be a potential treatment option to stop the progression of the disease. [Extracted from the article] |
|
Copyright of Journal of Neurology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
